96 related articles for article (PubMed ID: 15087619)
1. Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs.
Heerdt PM; Kang R; The' A; Hashim M; Mook RJ; Savarese JJ
Anesthesiology; 2004 Apr; 100(4):846-51. PubMed ID: 15087619
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: a comparison with mivacurium.
Savarese JJ; Belmont MR; Hashim MA; Mook RA; Boros EE; Samano V; Patel SS; Feldman PL; Schultz JA; McNulty M; Spitzer T; Cohn DL; Morgan P; Wastila WB
Anesthesiology; 2004 Apr; 100(4):835-45. PubMed ID: 15087618
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and cardiopulmonary side effects of CW002, a cysteine-reversible neuromuscular blocking drug in dogs.
Heerdt PM; Malhotra JK; Pan BY; Sunaga H; Savarese JJ
Anesthesiology; 2010 Apr; 112(4):910-6. PubMed ID: 20234311
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of GW280430A in humans.
Belmont MR; Lien CA; Tjan J; Bradley E; Stein B; Patel SS; Savarese JJ
Anesthesiology; 2004 Apr; 100(4):768-73. PubMed ID: 15087609
[TBL] [Abstract][Full Text] [Related]
5. Dose-response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man.
Heerdt PM; Sunaga H; Owen JS; Murrell MT; Malhotra JK; Godfrey D; Steinkamp M; Savard P; Savarese JJ; Lien CA
Anesthesiology; 2016 Dec; 125(6):1136-1143. PubMed ID: 27749289
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of doxacurium chloride. A new long-acting nondepolarizing muscle relaxant.
Basta SJ; Savarese JJ; Ali HH; Embree PB; Schwartz AF; Rudd GD; Wastila WB
Anesthesiology; 1988 Oct; 69(4):478-86. PubMed ID: 2972233
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of doxacurium chloride (BW A938U) in children.
Sarner JB; Brandom BW; Cook DR; Dong ML; Horn MC; Woelfel SK; Davis PJ; Rudd GD; Foster VJ; McNulty BF
Anesth Analg; 1988 Apr; 67(4):303-6. PubMed ID: 2965532
[TBL] [Abstract][Full Text] [Related]
8. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
Lien CA; Belmont MR; Abalos A; Eppich L; Quessy S; Abou-Donia MM; Savarese JJ
Anesthesiology; 1995 May; 82(5):1131-8. PubMed ID: 7537945
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats.
Wastila WB; Maehr RB; Turner GL; Hill DA; Savarese JJ
Anesthesiology; 1996 Jul; 85(1):169-77. PubMed ID: 8694363
[TBL] [Abstract][Full Text] [Related]
10. Cysteine reversal of the novel neuromuscular blocking drug CW002 in dogs: pharmacodynamics, acute cardiovascular effects, and preliminary toxicology.
Sunaga H; Malhotra JK; Yoon E; Savarese JJ; Heerdt PM
Anesthesiology; 2010 Apr; 112(4):900-9. PubMed ID: 20234310
[TBL] [Abstract][Full Text] [Related]
11. Neuromuscular and cardiovascular effects of doxacurium in children anaesthetized with halothane.
Goudsouzian NG; Alifimoff JK; Liu LM; Foster V; McNulty B; Savarese JJ
Br J Anaesth; 1989 Mar; 62(3):263-8. PubMed ID: 2522789
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacodynamics and clinical adverse effects of mivacurium. The effect of oral premedication with H1/H2 antagonists].
Mayer M; Doenicke A; Nebauer AE; Rosenberger C; Lorenz W; Peter K
Anaesthesist; 1993 Sep; 42(9):592-6. PubMed ID: 8105716
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic and hemodynamic effects of mivacurium in infants anesthetized with halothane and nitrous oxide.
Goudsouzian NG; Denman W; Schwartz A; Shorten G; Foster V; Samara B
Anesthesiology; 1993 Nov; 79(5):919-25. PubMed ID: 8239009
[TBL] [Abstract][Full Text] [Related]
14. Safety and potency of ANQ 9040 in male volunteers.
Munday IT; Jones RM; Donati F; Mant TG; Damask MC
Anesthesiology; 1994 Jan; 80(1):97-103; discussion 27A-28A. PubMed ID: 8291736
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of atracurium in infants.
Brandom BW; Woelfel SK; Cook DR; Fehr BL; Rudd GD
Anesth Analg; 1984 Mar; 63(3):309-12. PubMed ID: 6322615
[TBL] [Abstract][Full Text] [Related]
16. Mivacurium chloride (BW B1090U)-induced neuromuscular blockade during nitrous oxide-isoflurane and nitrous oxide-narcotic anesthesia in adult surgical patients.
Weber S; Brandom BW; Powers DM; Sarner JB; Woelfel SK; Cook DR; Foster VJ; McNulty BF; Weakly JN
Anesth Analg; 1988 Jun; 67(6):495-9. PubMed ID: 2967644
[TBL] [Abstract][Full Text] [Related]
17. Newer neuromuscular blocking agents: how do they compare with established agents?
Sparr HJ; Beaufort TM; Fuchs-Buder T
Drugs; 2001; 61(7):919-42. PubMed ID: 11434449
[TBL] [Abstract][Full Text] [Related]
18. The neuromuscular blocking and cardiovascular effects of doxacurium chloride in patients receiving nitrous oxide narcotic anesthesia.
Murray DJ; Mehta MP; Choi WW; Forbes RB; Sokoll MD; Gergis SD; Rudd GD; Abou-Donia MM
Anesthesiology; 1988 Oct; 69(4):472-7. PubMed ID: 3177909
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Pharmacology in the Rhesus Monkey of CW 1759-50, a New Ultra-short Acting Nondepolarizing Neuromuscular Blocking Agent, Degraded and Antagonized by L-Cysteine.
Savarese JJ; Sunaga H; McGilvra JD; Belmont MR; Murrell MT; Jeannotte E; Cooke FE; Wastila WB; Heerdt PM
Anesthesiology; 2018 Nov; 129(5):970-988. PubMed ID: 30212413
[TBL] [Abstract][Full Text] [Related]
20. Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.
Frampton JE; McTavish D
Drugs; 1993 Jun; 45(6):1066-1089. PubMed ID: 7691494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
